The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0748 GMT - Top Glove is likely to post weaker fiscal 4Q earnings on quarter, mainly due to lower sales volume and average selling prices, Hong Leong IB's Chee Kok Siang says in a note. "Customers are adopting a more cautious 'wait-and-see' approach, amid falling ASP and expectations of further price declines, before restocking," the analyst says. The glove maker's average selling price for generic medical nitrile gloves also appear to have peaked in May and declined for June and July orders. Hong Leong IB lowers its target price for the stock to 0.68 ringgit from 0.75 ringgit. Shares are 2.1% lower at 0.71 ringgit.(amanda.lee@wsj.com)

0142 GMT - Top Glove's sales volume is likely to decline by about 8% sequentially in fiscal 4Q, as buyers delay purchases in anticipation of further price declines, TA Securities analyst Tan Kong Jin says in a note. Nitrile butadiene rubber latex prices are expected to fall by about 38% in 2H, causing blended average selling prices to decline by between 6% and 10%, he reckons. Despite the near-term pressure on prices, the company plans to increase its effective production capacity to 72 billion gloves by the end of the current fiscal from 64 billion in FY 2025. TA Securities maintains a sell rating on Top Glove and maintains the target price at 0.65 ringgit. Shares are unchanged at 0.72 ringgit. (yingxian.wong@wsj.com)

0124 GMT - Top Glove's windfall earnings likely peaked in fiscal 3Q and are expected to trend toward more normal levels ahead, says CIMB Securities analyst Chun Sung Oong in a note. Oong attributes this to the easing of average selling prices from the peak levels of US$26-US$28 per 1,000 pieces since June. Profitability could moderate as selling prices come down and higher raw material costs filter through results, he says. A weaker pricing environment may cause customers to delay purchases as buyers anticipate further price declines, he adds. CIMB downgrades Top Glove's rating to reduce from hold on expectation of softer earnings and maintains a target price of 0.63 ringgit. Shares are 1.4% higher at 0.73 ringgit. (yingxian.wong@wsj.com)

0855 GMT - China's equities market may see increased growth in sectors beyond artificial intelligence, according to HSBC analysts in a research note. "The AI-centric rally has started to broaden out, with equity fundamentals now being the most important driver," they say. AI data-center-related sectors, such as the electronic fabrication and energy storage industries, are likely to become key beneficiaries, they say. Recently released economic data suggests domestic demand remains weak, so low-valuation sectors, such as consumer staples and healthcare, could take longer to bottom out, they say. (tracy.qu@wsj.com)

0839 GMT - BeOne Medicine's revenue is forecast to reach $6.5 billion in 2026, driven by flagship cancer drug Brukinsa, which helped turn its operating margins positive last year, Morningstar analyst Kai Wang says. He sees the stock as undervalued, citing potential sales growth of its chronic lymphocytic leukemia treatment Brukinsa and its other core product Beqalzi, which is projected to generate $1 billion in sales by 2035. Wang estimates margin expansion of 400 basis points over the long term, as Brukinsa continues to scale out and capture more market share. Beyond 2026, Morningstar forecasts Brukinsa revenue growth in the high teens annually before slowing to 6% by 2032, when its patent expires. It initiates coverage of BeOne's H-shares with a fair value estimate of HK$214. The stock closed at HK$163.70. (jason.chau@wsj.com)

(END) Dow Jones Newswires

June 19, 2026 04:20 ET (08:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.